DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Acceleron Pharma Inc. (XLRN)
« Back to company indexXLRN Chatter Timeline
Stock Ticker for XLRN
Most Active Tweeters for XLRN
| User | Tweets |
|---|---|
| @Tickeron | 10 |
| @1MinuteStock | 7 |
| @Gambiste1 | 6 |
| @StckPro | 4 |
| @otcdynamics | 3 |
Recent Tweets for XLRN
 |
@IlliniJJ $XLRN - Announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to revi… https://t.co/n78Tnl28Cz December 6th 2019, 5:12pm |
 |
@Gambiste1 RT @BioRunUp: $XLRN $BMY - FDA AdCom on 12/18 no longer required. PDUFA still 4/4/20 December 6th 2019, 2:12pm |
 |
@1MinuteStock Wondering about risks of $XLRN? The 21-day volatility is 19.71% https://t.co/JXwt944IOs December 6th 2019, 12:12pm |
 |
@SwingTradeBot Recent $XLRN technical alerts: NR7 plus 7 more alerts... https://t.co/9CITuDOmfh December 6th 2019, 12:12pm |
 |
@Biotech2050 Congrats $XLRN @AcceleronPharma $BMY @ScienceAtBMS No adcom required for luspatercept! https://t.co/YJMLcTNlXT December 6th 2019, 12:12pm |
 |
@AlertTrade DOWNSIDE MOMENTUM ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room December 6th 2019, 12:12pm |
 |
@StckPro $BMY $XLRN NEW ARTICLE : No Ad Com review for Bristol-Myers' luspatercept for MDS https://t.co/Bry4m0mGr6 Get all t… https://t.co/MW4n0KcnEg December 6th 2019, 12:12pm |
 |
@NateNs5 ? No Ad Com review for Bristol-Myers' luspatercept for MDS $BMY $XLRN https://t.co/TPVqA8zuFd December 6th 2019, 12:12pm |
 |
@pnani456 $XLRN $BMY Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® ...… https://t.co/dNkagwiwzk December 6th 2019, 12:12pm |
 |
@MarketCurrents $BMY $XLRN - No Ad Com review for Bristol-Myers' luspatercept for MDS https://t.co/YTvakZMTT3 December 6th 2019, 12:12pm |
 |
@BioRunUp $XLRN $BMY - FDA AdCom on 12/18 no longer required. PDUFA still 4/4/20 December 6th 2019, 12:12pm |
 |
@Sports_bios @bradloncar Too crazy - prolly someone hit the wrong buttons.. the only thing $XLRN and $BMY (ex-CELG) has in commo… https://t.co/TmkhrNDs0b December 6th 2019, 9:12am |
 |
@otcdynamics $XLRN Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of https://t.co/Tr3Of3lrqc December 6th 2019, 8:12am |
 |
@bradloncar This is weird news for $XLRN to be emailing out. How's that Celgene/Bristol integration going?… https://t.co/oJ5PXxtcQN December 5th 2019, 4:12pm |
 |
@Tickeron $XLRN in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/HWcWKeDxxJ December 5th 2019, 4:12pm |
 |
@OlympiaReport Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Analysts https://t.co/td8wRkPcgh December 4th 2019, 10:12pm |
 |
@WeekHerald Brokerages Set Acceleron Pharma Inc $XLRN Target Price at $58.70 https://t.co/Uu0ylIeimJ December 4th 2019, 10:12pm |
 |
@newsfilterio Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings $XLRN https://t.co/u8T0BnjFAw December 4th 2019, 8:12pm |
 |
@rungirl1104 Congratulations to $XLRN on this well deserved recognition https://t.co/2IXl7XIaZt December 4th 2019, 6:12pm |
|
@otcdynamics $XLRN Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings https://t.co/iIxxcYugGz December 4th 2019, 4:12pm |
 |
@ByJoFagg December 18 advisory committee meetings announced for #luspatercept in myelodysplastic syndrome $BMY $XLRN and… https://t.co/YEf0vJy7WL December 4th 2019, 11:12am |
|
@Biotech2050 Ccredit Suisse on $BMY partner $XLRN https://t.co/q6GShhOOTR December 3rd 2019, 11:12pm |
|
@Gambiste1 RT @TradeFlags: #GoldenCross $XLRN at 48.84 R15 HiLo 66% T1Y 59 buy fwdPE -23.0 DIV N/A #Acceleron #stocks #trading #finance #market http… December 3rd 2019, 10:12pm |
 |
@TradeFlags #GoldenCross $XLRN at 48.84 R15 HiLo 66% T1Y 59 buy fwdPE -23.0 DIV N/A #Acceleron #stocks #trading #finance… https://t.co/Kb6Yf0M5wp December 3rd 2019, 9:12pm |
|
@Gambiste1 RT @StckPro: $XLRN NEW ARTICLE : Stock Upgrades: Acceleron Pharma Shows Rising Relative Strength https://t.co/VN5fJCUdMS Get all the latest… December 3rd 2019, 1:12pm |
|
@StckPro $XLRN NEW ARTICLE : Stock Upgrades: Acceleron Pharma Shows Rising Relative Strength https://t.co/VN5fJCUdMS Get all… https://t.co/VfeOZPaqxi December 3rd 2019, 11:12am |
|
@NateNs5 FDA Ad Com set for Bristol-Myers' luspatercept for MDS $BMY $XLRN https://t.co/IgotHqeafh December 3rd 2019, 10:12am |
|
@Gambiste1 RT @1stOncology: #Acceleron to Host Conference Call and Webcast to Review Data Presented at #ASH19 $XLRN https://t.co/AU8gB8dwxL December 3rd 2019, 10:12am |
|
@Gambiste1 RT @Pelion2001: @BioStocks Last earnings call management anticipated a panel due to new mechanism of action so no surprise $XLRN December 3rd 2019, 10:12am |
 |
@NedPagliarulo FDA will hold an adcomm to review $BMY and $XLRN drug Reblozyl for its second indication in myelodysplastic syndrom… https://t.co/KmG61Tc7Eu December 3rd 2019, 9:12am |
|
@StckPro $BMY $XLRN NEW ARTICLE : FDA Ad Com set for Bristol-Myers' luspatercept for MDS https://t.co/nhTHIu7uxD Get all the… https://t.co/3N2DQrfzWN December 3rd 2019, 9:12am |
|
@MarketCurrents $BMY $XLRN - FDA Ad Com set for Bristol-Myers' luspatercept for MDS https://t.co/pipgn5wvBc December 3rd 2019, 9:12am |
 |
@1stOncology #Acceleron to Host Conference Call and Webcast to Review Data Presented at #ASH19 $XLRN https://t.co/AU8gB8dwxL December 3rd 2019, 9:12am |
 |
@Pelion2001 @BioStocks Last earnings call management anticipated a panel due to new mechanism of action so no surprise $XLRN December 3rd 2019, 9:12am |
 |
@semodough RT @BioStocks: $BMY & $XLRN Announce FDA Advisory Committee Will Review Reblozyl (luspatercept-aamt) for Use in Patients With Myelodysplast… December 3rd 2019, 8:12am |
 |
@BioStocks $BMY & $XLRN Announce FDA Advisory Committee Will Review Reblozyl (luspatercept-aamt) for Use in Patients With Myel… https://t.co/KONvfIcFPh December 3rd 2019, 7:12am |
|
@Gambiste1 RT @the_chart_life: $XLRN Acceleron Pharma ...I like it as long as it can stay above ~$48. https://t.co/53fFUbgxdt December 2nd 2019, 10:12pm |
 |
@the_chart_life $XLRN Acceleron Pharma ...I like it as long as it can stay above ~$48. https://t.co/53fFUbgxdt December 2nd 2019, 10:12pm |
 |
@DataTrials $XLRN Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease…NCT03124459. Estimated Primary Completion Date - 01/2020 December 2nd 2019, 8:12pm |
 |
@ConsumerFeed Acceleron Pharma Inc $XLRN Given Consensus Rating of “Buy” by Brokerages https://t.co/uB9BPwDK0D December 2nd 2019, 5:12pm |
 |
@bbnsnews Acceleron Pharma Inc $XLRN Receives $58.70 Consensus Target Price from Analysts https://t.co/uHXSGRhTNN December 2nd 2019, 5:12pm |
|
@Tickeron $XLRN in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on November 25, 2019. View od… https://t.co/m5NvXzdfnd December 2nd 2019, 2:12pm |
 |
@CentralChartsEN $XLRN #ACCELERONPHARMA - Daily: @AcceleronPharma ACCELERON PHARMA INC. is part of a very strong bullish trend. Trad… https://t.co/gW61t0ixCO December 2nd 2019, 2:12pm |
 |
@Londinia_IA $XLRN #ACCELERONPHARMA - Daily: ACCELERON PHARMA INC. is part of a very strong bullish trend. Traders may consider… https://t.co/ztNmdDiI78 December 2nd 2019, 2:12pm |
|
@AlertTrade UPSIDE MOMENTUM ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO0TZ6b to FREE Trading Room December 2nd 2019, 2:12pm |
|
@StckPro $TRV $XLRN NEW ARTICLE : Travelers Poised To Continue Its Impressive Streak Of Dividend Hikes https://t.co/oand15MJT2 December 2nd 2019, 9:12am |
 |
@SeekingAlpha $XLRN - Acceleron Heads Toward Commercial Success. Continue reading: https://t.co/rdj96Jm8r8 #investing #stocks #finance December 2nd 2019, 9:12am |
|
@otcdynamics $XLRN Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of https://t.co/RgvfAIk2Wb December 2nd 2019, 7:12am |
|
@TekATL3 $XLRN breaking higher here, good follow through and should break 60 December 2nd 2019, 7:12am |
 |
@parthar @BioBreakout Isn’t the $XLRN decision already out ? December 1st 2019, 10:12pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.